Há declínio da fala e da deglutição na Esclerose Lateral Amiotrófica ao longo de dez anos?
Is there a decline in speech and swallowing in Amyotrophic Lateral Sclerosis over ten years?
Regiani Alabarces Mendes; Ivonaldo Leidson Barbosa Lima; Mário Emílio Teixeira Dourado Júnior; Maria de Jesus Gonçalves
Resumo
Palavras-chave
Abstract
Purpose To analyze the evolution of speech and swallowing decline in patients with amyotrophic lateral sclerosis (ALS) over a ten-year period.
Methods A retrospective and longitudinal cohort study. Data were collected using the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) from 101 medical records of ALS patients treated at the multidisciplinary neuromuscular diseases clinic of a University Hospital over a ten-year period. The data were statistically analyzed, adopting a significance level of p<0.05.
Results The analysis of the studied functions indicated that speech, swallowing, and salivation are altered over ten years in ALS. There are differences in patterns between the variables sex and disease type concerning symptoms related to dysarthria and dysphagia in these individuals, which may indicate the rate of progression over a given time interval.
Conclusion There is a decline in speech and swallowing over ten years in ALS. The bulbar type leads to a faster decline in the studied functions than the spinal type.
Keywords
Referências
1 Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363-80.
2 Rodrigues LGO, Lima ILB, Dourado MET Jr, Gonçalves MJ. Parâmetros e tipos de avaliação da disartria na esclerose lateral amiotrófica. Audiol Commun Res. 2023;28:e2791.
3 Rugaitienė M, Damulevičienė G, Lesauskaitė V, Ulozienė I. Oropharyngeal dysphagia as the main expression of amyotrophic lateral sclerosis. Medicina. 2022;58(5):647.
4 Brandão BC, Galdino AS, Lourenção LG, Trindade GS, Silva MAOM, Silva RG. Correlação entre funcionalidade bulbar e penetração e/ou aspiração laringotraqueal na doença do neurônio motor. CoDAS. 2018;30(1):e20170056.
5 Souza GAD, Silva RG, Cola PC, Onofri SMM. Resíduos faríngeos nas disfagias orofaríngeas neurogênicas. CoDAS. 2019;31(6):e20180160.
6 Rong P, Yunusova Y, Wang J, Zinman L, Pattee GL, Berry JD, et al. Predicting speech intelligibility decline in amyotrophic lateral sclerosis based on the deterioration of individual speech subsystems. PLoS One. 2016;11(5):e0154971.
7 Hannaford A, Pavey N, van den Bos M, Geevasinga N, Menon P, Shefner JM, et al. Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis. Ann Neurol. 2021;89(5):979-86.
8 Lee J, Madhavan A, Krajewski E, Lingenfelter S. Assessment of dysarthria and dysphagia in patients with amyotrophic lateral sclerosis: review of the current evidence. Muscle Nerve. 2021;64(5):520-31.
9 Su WM, Cheng YF, Jiang Z, Duan QQ, Yang TM, Shang HF, et al. Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis. EBioMedicine. 2021;74:103732.
10 Mezzedimi C, Vinci E, Giannini F, Cocca S. Correlation between dysphonia and dysphagia evolution in amyotrophic lateral sclerosis patients. Logoped Phoniatr Vocol. 2021;46(3):118-25.
11 Shoesmith C. Palliative care principles in ALS. Handb Clin Neurol. 2023;191:139-55.
12 James E, Ellis C, Brassington R, Sathasivam S, Young CA. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Syst Rev. 2022;5(5):CD006981.
13 Guedes K, Pereira C, Pavan K, Valério BCO. Cross-cultural adaptation and validation of als Functional Rating Scale-Revised in Portuguese language. Arq Neuropsiquiatr. 2010;68(1):44-7.
14 Gomes AP, Costa B, Marques R, Nunes V, Coelho C. Kaplan-Meier survival analysis: practical insights for clinicians. Acta Med Port. 2024;37(4):280-5.
15 Hattori S, Komukai S, Friede T. Sample size calculation for the augmented logrank test in randomized clinical trials. Stat Med. 2022;41(14):2627-44.
16 Aiello EN, Pain D, Radici A, Aktipi KM, Sideri R, Appollonio I, et al. Cognition and motor phenotypes in ALS: a retrospective study. Neurol Sci. 2022;43(9):5397-402.
17 Torri F, Lopriore P, Montano V, Siciliano G, Mancuso M, Ricci G. Pathophysiology and management of fatigue in neuromuscular diseases. Int J Mol Sci. 2023;24(5):5005.
18 Costa JB, Pereira D, Duarte D, Viana M. Otolaryngologist’s role in the diagnosis of amyotrophic lateral sclerosis. BMJ Case Rep. 2021;14(2):e234504.
19 Ziegler W, Staiger A, Schölderle T. Profiles of dysarthria: clinical assessment and treatment. Brain Sci. 2023;14(1):11.
20 Stegmann G, Charles S, Liss J, Shefner J, Rutkove S, Berisha V. A speech-based prognostic model for dysarthria progression in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(7-8):599-604.
21 Simon NG, Turner MR, Vucic S, Al-Chalabi A, Shefner J, Lomen-Hoerth C, et al. Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol. 2014;76(5):643-57.
22 Arora H, Willcocks RJ, Lott DJ, Harrington AT, Senesac CR, Zilke KL, et al. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history. Muscle Nerve. 2018;58(5):631-8.
23 Kokaliaris C, Evans R, Hawkins N, Mahajan A, Scott DA, Sutherland CS, et al. Long-term comparative efficacy and safety of risdiplam and nusinersen in children with type 1 spinal muscular atrophy. Adv Ther. 2024;41(6):2414-34.
24 Ricci G, Bello L, Torri F, Schirinzi E, Pegoraro E, Siciliano G. Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy. Neurol Sci. 2022;43(Suppl 2):625-33.
25 Rutkove SB. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):384-93.
26 Otto LAM, Froeling M, van Eijk RPA, Asselman FL, Wadman R, Cuppen I, et al. Quantification of disease progression in spinal muscular atrophy with muscle MRI: a pilot study. NMR Biomed. 2021;34(4):e4473.
27 Cantisani TA. Is there a treatment effective and safe for sialorrhea in people with amyotrophic lateral sclerosis (ALS)? Summary of a Cochrane Systematic Review. Neurol Sci. 2023;44(9):3083-5.
28 Oliveira AF Fo, Silva GA, Almeida DM. Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review. Einstein. 2016;14(3):431-4.
29 Ribeiro M, Miquilussi PA, Gonçalves FM, Taveira KVM, Stechman-Neto J, Nascimento WV, et al. The prevalence of oropharyngeal dysphagia in adults: a systematic review and meta-analysis. Dysphagia. 2024;39(2):163-76.
30 Linden E Jr, Becker J, Schestatsky P, Rotta FT, Marrone CD, Gomes I. Prevalence of amyotrophic lateral sclerosis in the city of Porto Alegre, in Southern Brazil. Arq Neuropsiquiatr. 2013;71(12):959-62.
Submetido em:
28/05/2024
Aceito em:
21/08/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email